Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Perronne

Showing results (51-60 of 97) with videos related to

Pageof 10
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|April 27, 2007
Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?Firouzé Bani-Sadr, Lise Denoeud, Patrice Morand, et al.
Therapeutic Advances in Infectious Disease|March 21, 2019
Efficacy of cefoxitin for the treatment of urinary tract infection due to extended-spectrum-beta-lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolatesOlivia Senard, Frédérique Bouchand, Laurene Deconinck, et al.
Lancet (London, England)|May 23, 2006
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialJean-Louis Bresson, Christian Perronne, Odile Launay, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 27, 2009
Gamma glutamyl transferase elevation in HIV/Hepatitis C virus-coinfected patients during interferon-ribavirin combination therapyFirouzé Bani-Sadr, Nathanael Lapidus, Eric Rosenthal, et al.
The Journal of Antimicrobial Chemotherapy|November 5, 2024
Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trialAlexis Lacout, Xavier Azalbert, Corinne Reverbel, et al.
AIDS (London, England)|July 17, 2007
High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?Firouzé Bani-Sadr, Isabelle Goderel, Patrice Morand, et al.
Gut|March 17, 2007
Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patientsChristopher Payan, Adeline Pivert, Patrice Morand, et al.
Travel Medicine and Infectious Disease|April 24, 2013
Pasteurella infection after muraenidae bite in an HIV infected patientPierre de Truchis, Benjamin Davido, Faten El Sayed, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2002
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapyMarianne Savès, François Raffi, Jacqueline Capeau, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 22, 2009
Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients?Firouzé Bani-Sadr, Pierre Bedossa, Eric Rosenthal, et al.
Pageof 10

Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Journal of Acquired Immune Deficiency Syndromes (1999)|April 27, 2007
Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?Firouzé Bani-Sadr, Lise Denoeud, Patrice Morand, et al.
Therapeutic Advances in Infectious Disease|March 21, 2019
Efficacy of cefoxitin for the treatment of urinary tract infection due to extended-spectrum-beta-lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolatesOlivia Senard, Frédérique Bouchand, Laurene Deconinck, et al.
Lancet (London, England)|May 23, 2006
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialJean-Louis Bresson, Christian Perronne, Odile Launay, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 27, 2009
Gamma glutamyl transferase elevation in HIV/Hepatitis C virus-coinfected patients during interferon-ribavirin combination therapyFirouzé Bani-Sadr, Nathanael Lapidus, Eric Rosenthal, et al.
The Journal of Antimicrobial Chemotherapy|November 5, 2024
Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trialAlexis Lacout, Xavier Azalbert, Corinne Reverbel, et al.
AIDS (London, England)|July 17, 2007
High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?Firouzé Bani-Sadr, Isabelle Goderel, Patrice Morand, et al.
Gut|March 17, 2007
Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patientsChristopher Payan, Adeline Pivert, Patrice Morand, et al.
Travel Medicine and Infectious Disease|April 24, 2013
Pasteurella infection after muraenidae bite in an HIV infected patientPierre de Truchis, Benjamin Davido, Faten El Sayed, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2002
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapyMarianne Savès, François Raffi, Jacqueline Capeau, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 22, 2009
Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients?Firouzé Bani-Sadr, Pierre Bedossa, Eric Rosenthal, et al.
Pageof 10